Jenburkt Pharma Share Price

Jenburkt Pharmaceuticals Limited, with its corporate operations in Mumbai, functions as a pharmaceutical formulations manufacturing company in India. The company was incorporated on June 10, 1985 by the Bhuta family as a venture to diversify into the healthcare and pharmaceutical industry. Jenburkt Pharmaceuticals manufactures and markets a range of branded pharmaceutical products across multiple therapeutic areas, including pain management, analgesics, muscle relaxants, nutraceuticals, anti-arthritics, anti-infectives, anti-fungals, anti-ulcerants, aphrodisiacs, and anti-diabetics. The company operates its WHO-GMP approved state-of-the-art manufacturing plant located in Sihor in Gujarat and has a global presence with its products exported to several countries across the world, while its registered office is based in Mumbai, Maharashtra.

Jenburkt share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes of its numerous branded formulations, raw material costs including active pharmaceutical ingredients, capacity utilization rates at its Sihor facility, domestic prescription demand from over 100,000 doctors, and the performance of its various therapeutic segments. Jenburkt stock price is influenced by various factors such as earnings, regulatory approvals from bodies like the CDSCO, changes in drug pricing policies under the National Pharmaceutical Pricing Authority (NPPA), and the continuous launch of new high-quality products. In the longer run, strategies such as expanding its international footprint, introducing innovative products, and strengthening its domestic sales force affect the stock market perceptions. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Jenburkt live share price provides real-time information about the last price traded, bid and ask prices, and trading volume. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Jenburkt live price helps in observing short-term price volatility and shows how a stock moves relative to the broader BSE Healthcare index. Furthermore, monitoring Jenburkt stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Jenburkt Pharmaceuticals Limited Company Fundamentals

a. Company Background

Jenburkt Pharmaceuticals Limited was incorporated on June 10, 1985 as a venture to diversify into the healthcare and pharmaceutical industry by the Bhuta family. The company is engaged in the manufacturing, producing, developing, and marketing of a range of branded pharmaceuticals and healthcare products. The company operates primarily in the pharmaceutical formulations segment, supplying products for various therapeutic areas including analgesic and antipyretics, anthelmintics, anti-arthritics, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants, aphrodisiac, muscle relaxants, nutraceuticals, and pain management. Its manufacturing operations are based in India, with a WHO-GMP approved state-of-the-art plant located in Sihor, Gujarat, while corporate functions are managed from its administrative office in Mumbai, Maharashtra. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and international markets. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in chronic and acute therapies, and input cost fluctuations.

b. Company Product Lines

• Pain management and analgesics include products for neuropathic pain and muscle relaxation, addressing a wide range of patient needs in the pain therapy segment

• Anti-infectives and anti-fungals cover a broad spectrum of medications used to treat bacterial and fungal infections across various patient demographics

• Gastrointestinal and metabolic care includes anti-ulcerants, antacids, and anti-diabetic medications for the management of chronic conditions

• Women’s health and nutraceuticals include aphrodisiacs and nutritional supplements catering to specific healthcare requirements

• Consumer healthcare products are available over-the-counter for common ailments, making essential medications accessible to the general public

The product portfolio is structured to serve both domestic demand and select international markets.

c. Company Revenue Model

• Domestic sales of branded formulations: The company generates revenue through sales of its pharmaceutical products to distributors, hospitals, and retail pharmacies across India

• Export sales to international markets: The company contributes revenue from customers in select global markets, leveraging its international presence

• Institutional and government tenders: The company earns revenue through supply agreements with large-scale healthcare institutions and government procurement agencies

• Contract manufacturing services: The company may provide manufacturing services to other pharmaceutical companies, utilizing its WHO-GMP approved facility

Revenue performance is primarily influenced by demand for pharmaceutical products, raw material costs, regulatory pricing policies, and selling price realizations in domestic and export markets.

d. Geographic Presence

• The primary manufacturing facility is located at Sihor, Gujarat

• The registered and corporate office is situated in Mumbai, Maharashtra

• The distribution network covers the domestic market across India through a robust sales force promoting its brands to over 100,000 doctors

• Export markets supply products to a growing list of countries across the globe

e. Key Milestones

• 1985: Incorporation of the company by the Bhuta family

• 2021-22: The annual report documented total assets and a steady financial performance over the years

• 2025: Filing of the annual report containing audited financial statements, auditors’ report, and directors’ report for FY 2024-25

• Recent years: Continued focus on product mix optimisation, operational efficiency improvements, and strategic expansion into new international markets

f. Industry Perspective

The pharmaceutical manufacturing industry is research-intensive and closely linked to demand from healthcare providers, hospitals, and retail pharmacies. Demand trends are influenced by disease prevalence, healthcare access, insurance coverage, and growth in chronic disease management driven by lifestyle changes. The industry is also affected by fluctuations in raw material prices such as active pharmaceutical ingredients and excipients, along with energy and logistics costs. Regulatory requirements and drug price controls on the NLEM (National List of Essential Medicines) are increasingly shaping production practices and capital investment decisions. Companies in the sector must manage patent expirations, generic competition, and pricing pressure while maintaining operational efficiency. These factors collectively influence financial performance and investor perception of firms like Jenburkt Pharmaceuticals.

Jenburkt Pharmaceuticals Limited Stock Market Presence: Listings & Index Representation

Jenburkt Pharmaceuticals Limited is listed on the National Stock Exchange (NSE) under the symbol JENBURPH and on the Bombay Stock Exchange (BSE) with the scrip code 524731. Jenburkt share price is actively traded on both exchanges. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Jenburkt stock price is generally tracked by investors interested in the pharmaceutical and healthcare industry.

Jenburkt Pharmaceuticals Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap and BSE Healthcare indices. Jenburkt share price finds representation in these indices based on its market standing. Jenburkt stock price presence in these indices helps investors track the company relative to other pharmaceutical and healthcare companies.

Jenburkt Pharmaceuticals Limited Stock Performance and Share Price History

Jenburkt share price on the NSE reflects its position as a branded pharmaceutical formulations manufacturer serving a wide range of therapeutic areas across India. Its performance is qualitatively driven by factors such as manufacturing capacity utilization at its Sihor facility, management of raw material costs including APIs, growth in domestic prescription volumes, and the ability to control operational expenses. Investors compare the Jenburkt share price movement with other pharmaceutical companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported Jenburkt share price. Beyond operational and sector influences, corporate actions such as the company’s expansion into new therapeutic areas and the launch of innovative products can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by drug price controls and patent regulations.

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by the stock’s annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger prescription demand and stable margins, whereas a significant low aligns with market corrections or sector volatility. Jenburkt share price extremes reflect the impact of drug pricing policies, global pharmaceutical trends, and earnings visibility, providing a framework for understanding historical performance.

Jenburkt stock price behaviour mirrors the trading patterns of a small-cap pharmaceutical company within India’s healthcare manufacturing ecosystem. The company’s diversified portfolio spanning pain management, anti-infectives, anti-diabetics, nutraceuticals, and consumer products has shaped its price history. Over the past five years, the stock has delivered positive annual returns in most years, generating a strong compound annual growth rate. However, the stock has also faced periods of short-term price declines. The stock has shown relatively lower volatility compared to the broader market, with a beta factor indicating a stable price movement pattern.

The company’s performance has closely tracked India’s pharmaceutical demand and domestic prescription trends. Positive momentum appeared during periods of strong demand for its core therapeutic offerings. However, periods of high raw material costs, pricing pressure from regulatory bodies, and competitive pressures have led to consolidation in Jenburkt share price. Profitability has shown consistent patterns, supported by the company’s lean operating structure and focus on high-quality branded products.

Despite COVID-19 disruptions, Jenburkt shares showed resilience during the pandemic recovery phase. While the broader pharmaceutical sector faced supply chain challenges, the company’s diversified product mix and established doctor relationships helped Jenburkt share price recover from pandemic lows. The company maintains a sizeable workforce and supplies products to patients across India with a wide distribution network. It has also operated at consistent capacity utilization levels across its manufacturing plant.

Jenburkt share price today has declined for several recurring reasons. A drop in prescription demand or pricing pressure on key brands directly impacts profitability and can lead to selling pressure. Changes in government policy such as price revisions under the Drug Price Control Order for essential medicines can also cause Jenburkt share price to fall. Moreover, increases in operational costs without matching price increases compress margins, making the stock less attractive. Periods of increased regulatory scrutiny that affect product approvals raise concerns about future revenue streams, leading to declines. The stock remains sensitive to raw material price movements; if API costs rise significantly, it can cause Jenburkt share price to fall as investors adjust expectations for future margin growth. Broader market sell-offs in small-cap stocks also pull Jenburkt share price down, regardless of the company’s individual performance. A slowdown in export demand or reduced prescription volumes in any product category directly affects revenue, resulting in a lower valuation.

Jenburkt Pharmaceuticals Limited Investor Relevance and Role in Portfolio

Jenburkt Pharmaceuticals Limited is a holding in small-cap and healthcare sector portfolios, offering exposure to branded pharmaceutical formulations across multiple therapeutic areas. Its inclusion in healthcare indices underscores its importance in India’s pharmaceutical manufacturing space. The company’s legacy of manufacturing high-quality, affordable medicines since the mid-1980s, together with its diversified product portfolio, makes it a consideration for long-term allocations.

Jenburkt share price receives influence from the company’s ownership structure. Jenburkt equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of around 46.65 percent, reflecting strong internal control by the Bhuta family. Foreign institutional investors currently hold no stake in the company. Domestic institutional investors maintain a very modest holding of approximately 0.12 percent. Mutual funds do not hold any stake in the company. The public holds the remaining stake, representing approximately 43 percent of the shares. The company’s management includes Ashish Uttam Bhuta as Chairman and Managing Director, and Dilip H. Bhuta as Whole Time Director and Chief Financial Officer. This investor base, with stable promoter participation and minimal institutional influence, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing.

Beyond fundamentals and ownership, the stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on raw material prices, prescription trends, and regulatory policy actions. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the healthcare sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as price control revisions.

Technical indicators provide additional insight into short-term momentum shifts in Jenburkt stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader healthcare sector trends. Based on available data, the stock’s beta indicates lower volatility compared to the broader market, reflecting its stable price movement pattern. The company maintains a near-zero debt to equity ratio, indicating a very low use of leverage. Return on equity and return on capital employed are at healthy levels, and the company’s book value per share is a reference point for valuation.

Overall, Jenburkt demonstrates a lower volatility profile compared to the broader market, with the stock generally considered to have below-average systematic risk. This makes it less sensitive to broader market movements but still responsive to sector-specific factors such as raw material price fluctuations and drug pricing regulations.

Jenburkt Pharmaceuticals Limited Sectoral Relevance and Peer Positioning

Jenburkt Pharmaceuticals Limited sector relevance stems from its over three-decade presence in the pharmaceutical industry since 1985, its position as a manufacturer of branded pharmaceutical formulations covering a wide range of therapeutic areas including pain management, anti-infectives, anti-diabetics, and nutraceuticals, its WHO-GMP approved manufacturing plant located in Sihor in Gujarat, its extensive domestic reach promoting its brands to over 100,000 doctors in India, its international presence with exports to a growing number of countries globally, and its legacy of manufacturing high-quality, affordable medicines, establishing it as a focused small-cap pharmaceutical provider supporting India’s healthcare ecosystem. Peer comparisons with companies like Venus Remedies, Bal Pharma, Godavari Drugs, and Aarey Drugs focus on product mix, therapeutic presence, regulatory compliance, and quality certifications rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of drug pricing policies, healthcare demand trends, and competitive dynamics further highlights Jenburkt Pharmaceuticals positioning within India’s broader pharmaceutical manufacturing market.

Jenburkt market cap highlights its position as a small-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization fluctuates within a range depending on the reporting period. The market cap has moved in line with investor perceptions of the company’s growth potential following consistent financial performance and expansion into new product categories. From earlier years through more recent periods, Jenburkt market cap showed an increasing trend as the company maintained its focus on operational efficiency and product portfolio rationalization, followed by phases of consolidation. This pattern reflects sustained investor confidence during favourable healthcare cycles, followed by price discovery during challenging periods impacted by pricing pressure and competitive dynamics. This movement mirrors the movement in the share price from its annual high to recent levels.

Jenburkt earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed trends supported by the core pharmaceutical business. Based on available data, the company’s revenue from operations increased from previous fiscal periods to more recent periods, driven by steady domestic demand and consistent export contributions. Total income moved upward over the same period. Profit after tax showed growth patterns aligned with prescription volumes and cost structures. However, quarterly performance has shown variability, with total income in recent quarters rising compared to previous quarters and also compared to corresponding quarters of prior years, while profit after tax has shown a decline in certain quarters. The company’s domestic sales have shown consistent growth in recent fiscal periods compared to prior years. Jenburkt earnings have faced headwinds from fluctuating raw material costs, pricing pressure from regulatory bodies, and competitive pressures from larger pharmaceutical players. However, the company has maintained its focus on operational efficiency, high-quality manufacturing, and consistent product supply. These developments illustrate the nature of the pharmaceutical industry and the company’s consistent position within this sector.

Jenburkt EPS provides insight into its operational performance and income generation from branded formulations across pain management, anti-infectives, anti-diabetics, and nutraceuticals. The company reported certain levels of basic EPS in recent quarters that showed movement compared to previous quarters and corresponding quarters of prior years, indicating performance trends. The trailing twelve-month EPS stands at certain levels depending on the reporting period. Jenburkt EPS for recent full fiscal years showed patterns compared to prior fiscal years, reflecting the impact of prescription demand cycles and cost structures. The company maintains a certain face value per share and continues to be promoted by the Bhuta family. More recent quarterly performance suggests that EPS has shown movement as the company navigates a competitive landscape while maintaining its focus on operational efficiency.

Jenburkt P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from branded pharmaceutical formulations. Based on available data, the current P/E ratio stands at a significant discount to the industry average, indicating that the stock trades at a lower multiple compared to its peers. The company’s profit after tax has shown consistent patterns from previous fiscal years to the most recent fiscal year. Quarterly performance has demonstrated variability, with profit after tax showing increases in some quarters and declines in others, accompanied by movement in total income on a quarter-on-quarter basis. Jenburkt P/E ratio reflects how market sentiment evolves alongside the company’s operational performance in a competitive industry. The company’s earnings before interest and taxes for recent quarters stood at levels reflecting operating efficiency. The net profit margin has shown movement in recent quarters compared to same quarters of prior years, indicating how the company manages cost structures and pricing power in a competitive pharmaceutical market.

Summary

Jenburkt Pharmaceuticals Limited operates as a small-cap branded pharmaceutical manufacturer with a history dating back to 1985. Jenburkt share price gets influenced by prescription demand, raw material costs, drug pricing regulations, and the company’s distribution network of over 100,000 doctors. The company’s WHO-GMP certified facility and diversified product portfolio support its market position. Jenburkt stock price reflects operational execution within the competitive pharmaceutical sector. The ownership structure shows stable promoter holding of around 46 percent with minimal institutional participation and a significant retail majority.